Posted on Leave a comment

Medical Cannabis and Cannabinoids for Impaired Sleep: A Systematic Review and Meta-Analysis of Randomized Clinical Trials*

logo Sleep
Désolé, vous n’êtes pas autorisé-e à voir ce contenu. Pour voir cette page, il  faut vous connecter à votre compte avec privilège.

Sorry, you are not authorized to view this content. To view this page, you must log into your account with privilege.

Login

NOUVELLE INSCRIPTION / NEW REGISTRATION

Si vous n’avez pas encore de compte avec privilège, il est nécessaire de nous envoyer une demande spécifique par courriel (info@86avenue.ch) après création d’un compte standard. Des justificatifs pourrons vous être demandés, confirmant votre statut de personne impliquée dans le domaine médical ou titulaire d’une autorisation. Un privilège sera ensuite attribué à votre profil.

Vous pouvez également remplir le FORMULAIRE D‘INSCRIPTION pour l’obtention du privilège. Ce service est TOTALEMENT GRATUIT.

En vous enregistrant sous votre profil avec privilège, vous pourrez accéder aux articles médicaux et assimilés, ainsi qu’à leurs résumés. Nous regrettons cette situation qui pourrait exposer notre entreprise à des sanctions légales.

 

If you do not yet have a privileged account, it is necessary to send us a specific request by email (info@86avenue.ch) after creating a standard account. Evidence may be requested, confirming your status as a person involved in the medical field or holder of an authorization. A privilege will then be assigned to your profile.

You can also complete the REGISTRATION FORM for obtaining the privilege. This service is TOTALLY FREE.

By registering under your profile with privilege, you will be able to access medical and similar articles, as well as their summaries. We regret this situation which could expose our company to legal sanctions.

Posted on Leave a comment

Cannabis use in patients with insomnia and sleep disorders: Retrospective chart review

logo CPJRPC
Désolé, vous n’êtes pas autorisé-e à voir ce contenu. Pour voir cette page, il  faut vous connecter à votre compte avec privilège.

Sorry, you are not authorized to view this content. To view this page, you must log into your account with privilege.

Login

NOUVELLE INSCRIPTION / NEW REGISTRATION

Si vous n’avez pas encore de compte avec privilège, il est nécessaire de nous envoyer une demande spécifique par courriel (info@86avenue.ch) après création d’un compte standard. Des justificatifs pourrons vous être demandés, confirmant votre statut de personne impliquée dans le domaine médical ou titulaire d’une autorisation. Un privilège sera ensuite attribué à votre profil.

Vous pouvez également remplir le FORMULAIRE D‘INSCRIPTION pour l’obtention du privilège. Ce service est TOTALEMENT GRATUIT.

En vous enregistrant sous votre profil avec privilège, vous pourrez accéder aux articles médicaux et assimilés, ainsi qu’à leurs résumés. Nous regrettons cette situation qui pourrait exposer notre entreprise à des sanctions légales.

 

If you do not yet have a privileged account, it is necessary to send us a specific request by email (info@86avenue.ch) after creating a standard account. Evidence may be requested, confirming your status as a person involved in the medical field or holder of an authorization. A privilege will then be assigned to your profile.

You can also complete the REGISTRATION FORM for obtaining the privilege. This service is TOTALLY FREE.

By registering under your profile with privilege, you will be able to access medical and similar articles, as well as their summaries. We regret this situation which could expose our company to legal sanctions.

Posted on Leave a comment

Treating Insomnia Symptoms with Medicinal Cannabis: A Randomized, Cross-Over Trial of the Efficacy of a Cannabinoid Medicine Compared with Placebo

logo Sleep®
Désolé, vous n’êtes pas autorisé-e à voir ce contenu. Pour voir cette page, il  faut vous connecter à votre compte avec privilège.

Sorry, you are not authorized to view this content. To view this page, you must log into your account with privilege.

Login

NOUVELLE INSCRIPTION / NEW REGISTRATION

Si vous n’avez pas encore de compte avec privilège, il est nécessaire de nous envoyer une demande spécifique par courriel (info@86avenue.ch) après création d’un compte standard. Des justificatifs pourrons vous être demandés, confirmant votre statut de personne impliquée dans le domaine médical ou titulaire d’une autorisation. Un privilège sera ensuite attribué à votre profil.

Vous pouvez également remplir le FORMULAIRE D‘INSCRIPTION pour l’obtention du privilège. Ce service est TOTALEMENT GRATUIT.

En vous enregistrant sous votre profil avec privilège, vous pourrez accéder aux articles médicaux et assimilés, ainsi qu’à leurs résumés. Nous regrettons cette situation qui pourrait exposer notre entreprise à des sanctions légales.

 

If you do not yet have a privileged account, it is necessary to send us a specific request by email (info@86avenue.ch) after creating a standard account. Evidence may be requested, confirming your status as a person involved in the medical field or holder of an authorization. A privilege will then be assigned to your profile.

You can also complete the REGISTRATION FORM for obtaining the privilege. This service is TOTALLY FREE.

By registering under your profile with privilege, you will be able to access medical and similar articles, as well as their summaries. We regret this situation which could expose our company to legal sanctions.

Posted on Leave a comment

The cannabis sales regulation project validated in the canton of Vaud*

Flag of Switzerland

« The effects of regulated non-profit cannabis sales on consumer behavior and its impact on the illegal market. »

Emilie Moeschler, municipal in social cohesion

The Lausanne project for the regulated sale of cannabis is taking shape. Entitled Cann-L, the pilot trial has received authorization from the Federal Office of Public Health, thus joining the projects already validated in Basel and Zurich, reports the RTS.*

People wishing to participate in this study – 2000 have already expressed their interest on the project’s website – will be able to register in June. The place of sale, which is not yet known, should open in September, the City of Lausanne indicated on Tuesday.* The Vaudois capital and its partner Addiction Suisse, which is leading the scientific part of the project, hope to bring together a panel of around 1,200 people who use cannabis and live in Lausanne.*

The products will be available in a single point of sale and without medical connotation. Several premises are currently being evaluated.* The sales team is being formed. This will provide advice on consumption and risk reduction, as well as reminders on the legislation in force. It will also be able to “evaluate and guide people with problematic consumption in the support network”, specifies the City of Lausanne.*

On sale by September*

“After the Cantonal Ethics Commission, the authorization of the OFSP marks a major step for our project”, commented Emilie Moeschler, the municipal councilor for social cohesion, quoted in the press release. She added that the concrete phase could now start with, as a first step, the launch of registrations.*

Necessary for the study, the “local and organic” cultivation of the plants can also begin. The first harvest will take place during the summer. This will be followed by a period of preparation of the products before they go on sale by September.*

These products will be intended “for personal consumption and in the private sphere”, underlines the Vaud capital. And to recall that it seeks to study, via this pilot project, “the effects of the regulated sale of non-profit cannabis on the behavior of consumers as well as its impact on the illegal market.”*

The project should thus make it possible to better understand consumption, but also strengthen prevention. In terms of security, it is a question of limiting the nuisance caused by the illegal market.*

* original article

** image

*** ndlr. : –.

Posted on Leave a comment

Raphael Mechoulam has passed away at the age of 92*

Flag of Israel

« His research group discovered the first endocannabinoid in 1992, which he named anandamide. »

International Alliance for Cannabinoid Medicines (IACM)

On 9 March 2023, Raphael Mechoulam, professor emeritus of medicinal chemistry at the Hebrew University in Jerusalem, passed away at his home in Jerusalem at the age of 92. He is often referred to as the father or grandfather of cannabinoid research because of his ground-breaking discoveries. He had first determined the exact chemical structure of the cannabis active ingredient delta-9-THC in 1964, together with Yehiel Gaoni, and his research group discovered the first endocannabinoid in 1992, which he named anandamide.*

Raphi, as he was called by his friends, enjoyed high international recognition not only because of his great scientific achievements, but also because of his impressive personality, which made him a role model and inspiration for many scientists. He contributed significantly to improving the lives of thousands and thousands of people with severe diseases through cannabis treatment. We were fortunate and honoured to have him as a member of the IACM Board of Directors for many years and as Chairman of the IACM from 2003-2005. Among many other awards given to him during his life, he received the IACM Special Award in 2014 for his contributions to the re-introduction of cannabis and cannabinoids into medicine.*

We will miss him. He will live on in our hearts.*

* original article

** image

*** ndlr. : –.

Posted on Leave a comment

Vaud wants to supervise future cannabis sales pilot trials*

Flag of Switzerland

« The canton does not intend to launch a trial of this type itself, but it supports the principle. »

The Vaud government

The Vaud Council of State wants to supervise pilot trials for the sale of cannabis for non-medical purposes. The Lausanne Cann-L project will be the first to see the light of day in the canton, after the final authorization from the Federal Office of Public Health (OFSP), reports RTS.*

The Vaudois government submits to the Grand Council a draft decree which specifies the role of the cantonal authorities in monitoring and supervising the pilot projects. This is particularly the case in terms of safety and public health.*

Support for the principle of such trials*

The canton does not intend to launch a trial of this type itself, but it supports the principle, he explains in a press release on Thursday.*

In particular, it is planned to set up a monitoring and control commission. It will be responsible, in association with the FOPH, for monitoring the implementation of the trials, their coordination and the processing of any reports and complaints. This commission will be chaired by the cantonal doctor and will bring together experts, representatives of the municipalities and of justice and police circles.*

The canton will contribute to the financing of the scientific part of the trial. For this purpose, he is requesting an amount of 525,000 francs for three years.*

Dedicated store in the center of Lausanne*

On May 20, Lausanne presented its cannabis sales pilot project. The objective is to measure the effects of a regulated sales model on consumers and drug trafficking. Cannabis should be sold in a dedicated store downtown.*

A first study on the regulated sale of cannabis began at the end of January in pharmacies in Basel. Other projects are awaiting final authorization from the FOPH, notably in Zurich, Lausanne and Geneva.*

* original article

** image

*** ndlr. : –.

Posted on Leave a comment

Start of the pilot project for the sale of cannabis in pharmacies in Basel*

Flag of Switzerland

« 374 people who all regularly consume cannabis will benefit from this study. »

RTS

The city of Basel has been offering cannabis for sale in nine pharmacies since Monday. This pilot project, the first in Switzerland, offers a “regulated” sale reserved for around 370 participants. The goal: to study the health effects of a legal distribution of this type of product, reports RTS.*

The legal basis at the federal level to launch this pilot project, called “Weed care”, came into force in 2021. The Basel project is carried out jointly by the cantonal Department of Health, university psychiatric clinics, as well as psychiatric services in Aargau and the University of Basel.*

In French-speaking Switzerland, the cities of Lausanne and Geneva are on edge with a similar pilot project. All that is missing is the green light from the Federal Office of Public Health to be able to launch the production of cannabis and the recruitment of participants in the study.*

More than 370 people concerned*

In Basel, 374 people who all regularly consume cannabis will benefit from this study. It is a little over 300 men, about sixty women and six non-binary people. The youngest is 18, the oldest 76. The average age is 36.*

From today, a first group of around 180 people can buy cannabis products. The second group will start in six months. They will all receive questionnaires on their consumption habits and their health at two-month intervals. An interim report for the attention of the Federal Office of Public Health will be drawn up within a year.*

How to get cannabis*

In addition to their identity card, the participants will have to present a kind of student card which allows them to stock up in nine pharmacies located in different districts of the city of Basel.*

Two products based on hashish and four products based on cannabis flowers, all made in Switzerland, are offered to them with more or less THC, the main active molecule of cannabis intended to provide the feeling of relaxation.*

Prices will align with the local black market, i.e. between 8 and 12 francs per gram, depending on the product and the THC content.*

* original article

** image

*** ndlr. : –.

Posted on Leave a comment

Hemp brings hope for a better world to the UN*

CNUCED - UNCTAD

« In the European Union, one must respect one microgram per kilo of body weight, against seven in Switzerland. This tolerance does not however have an intoxicating effect. Nobody in Switzerland has ever suffered because of ‘a bread produced with hemp flour. This is a very safe bet that Europe should follow. »

Lorenza Romanese, director of the European Industrial Hemp Association

What if hemp was the plant of the future? The UN Conference for Trade and Development (UNCTAD) brought together industry players and representatives of States interested in this plant with multiple virtues on Wednesday in Geneva, reports RTS.*

The United Nations is convinced that legal cannabis is one of the keys to sustainable development. Largely under-exploited, its virtues are nevertheless numerous. This superfood grows easily, enriches the soil and is a super ecological textile fiber. Its cultivation requires, for example, 70% less water than cotton and almost no pesticides.*

Hemp can also be used for the manufacture of ecological building material. In this respect, France is a pioneer. “Thirty years ago, France was the first to develop a construction system based on the use of lime mixed with a part of hemp”, explains in La Matinale Pascal Mortoire, member of the French umbrella organization of hemps. *

He develops: “The shiv, the woody part of hemp which contains lignin, has several interesting properties. It is in particular a perfect insulator. It makes an absolutely incredible construction and insulation material, which resists fire, which allows use in all rooms. This allows the use of far fewer petroleum-based products.*

Exploited massively in the past*

Despite all these qualities, hemp is hardly cultivated. “The area at the global level dedicated to the cultivation of legal hemp corresponds to less than 0.02% of cultivated areas. There is therefore potential”, explains Marco Fugazza, economist at UNCTAD.*

However, hemp has not always been shunned so much. For centuries, until the 1940s, it was exploited massively in Europe, before being abandoned.*

“We substituted natural fibers with synthetic fibers – a synthetic derivative of petroleum – which came mostly from the United States,” explains Lorenza Romanese, director of the European Industrial Hemp Association.*

She explains that the plant has also fallen victim to its bad reputation: “Hemp ended up in the same basket as high-THC cannabis, and it was demonized. It all came from the United States, with a decision of Congress in 1937 to banish the entire botanical category of Cannabis sativa L.”*

The climatic argument should, however, favor its return to grace. “A hectare of classic hemp succeeds in trapping more carbon in five or six months than a hectare of primary forest. It’s absolutely incredible, it sequesters between ten and fourteen tons of carbon per year, and that without the use of pesticides and with very little fertiliser”, enthuses Pascal Mortoire.*

Legislative barriers*

Now, the ball is more than ever in the legislators’ court. Hemp cultivation suffers from numerous legal barriers, particularly in the European Union. Switzerland is a model student for some of its applications.*

“In terms of food, Switzerland is very advanced. It allows a much higher content of THC in foods, such as flour, products derived from the seed and hemp oil”, lists Lorenza Romanese.*

And to conclude: “In the European Union, one must respect one microgram per kilo of body weight, against seven in Switzerland. This tolerance does not however have an intoxicating effect. Nobody in Switzerland has ever suffered because of ‘a bread produced with hemp flour. This is a very safe bet that Europe should follow”.*

* original article

** image

*** ndlr. : –.

Posted on Leave a comment

Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo controlled randomized clinical trial

Frontiers in medicine
Désolé, vous n’êtes pas autorisé-e à voir ce contenu. Pour voir cette page, il  faut vous connecter à votre compte avec privilège.

Sorry, you are not authorized to view this content. To view this page, you must log into your account with privilege.

Login

NOUVELLE INSCRIPTION / NEW REGISTRATION

Si vous n’avez pas encore de compte avec privilège, il est nécessaire de nous envoyer une demande spécifique par courriel (info@86avenue.ch) après création d’un compte standard. Des justificatifs pourrons vous être demandés, confirmant votre statut de personne impliquée dans le domaine médical ou titulaire d’une autorisation. Un privilège sera ensuite attribué à votre profil.

Vous pouvez également remplir le FORMULAIRE D‘INSCRIPTION pour l’obtention du privilège. Ce service est TOTALEMENT GRATUIT.

En vous enregistrant sous votre profil avec privilège, vous pourrez accéder aux articles médicaux et assimilés, ainsi qu’à leurs résumés. Nous regrettons cette situation qui pourrait exposer notre entreprise à des sanctions légales.

 

If you do not yet have a privileged account, it is necessary to send us a specific request by email (info@86avenue.ch) after creating a standard account. Evidence may be requested, confirming your status as a person involved in the medical field or holder of an authorization. A privilege will then be assigned to your profile.

You can also complete the REGISTRATION FORM for obtaining the privilege. This service is TOTALLY FREE.

By registering under your profile with privilege, you will be able to access medical and similar articles, as well as their summaries. We regret this situation which could expose our company to legal sanctions.

Posted on Leave a comment

Hong Kong to ban CBD*

Flag of Hong Kong

« The trade and the public should arrange early disposal of any CBD products in their possession to avoid contravention of the law. »

government spokesperson

Cannabis extract to be put in the same category as heroin and cocaine, reports the Hong Kong Post.*

Hong Kong will outlaw cannabidiol (CBD) by February, the government announced on Thursday, placing it in the same category as heroin, cocaine and methamphetamine with users facing hefty jail time. The move is expected to wipe out businesses in the Chinese finance hub that had, until now, been able to sell CBD-infused products such as beers, coffee and health supplements.*
The changes to Hong Kong’s drug control laws, pending a final round of vetting by the city’s rubber-stamp legislature, will take effect from Feb 1.*
“The trade and the public should arrange early disposal of any CBD products in their possession to avoid contravention of the law,” a government spokesperson said.*
After the deadline, anyone who possesses or consumes CBD faces up to seven years in jail and fines of up to HK$ 1 million (US$ 127,000). CBD will be put alongside more than 200 substances classified as “dangerous drugs”, which all carry the same strict penalty.*
CBD is one of the active ingredients of cannabis but does not have psychoactive properties. Users have touted its relaxing and pain-relieving properties, though Hong Kong’s Security Bureau said such claims “lack authoritative scientific proof”.*
CBD is legal in some Asian nations including Thailand and Japan, as well as in the United States and parts of Europe.
John Lee, a former police officer who became Hong Kong’s chief executive in July, has taken a hard line on drugs.*
“Cannabis is a drug, and the government will categorise CBD as a dangerous drug … to protect the public’s health,” he said in a speech last month.*
China last year banned the use of CBD in cosmetic products.*

* article original

** image

*** ndlr. : –.